Home > Pulmonology > ERS 2022 > Does vilobelimab reduce mortality in severe COVID-19?

Does vilobelimab reduce mortality in severe COVID-19?

Presented By
Prof. Alexander Vlaar, Amsterdam UMC, the Netherlands
ERS 2022
Phase 3, PANAMO
Vilobelimab may reduce mortality in patients with severe COVID-19 pneumonia, the phase 3 PANAMO trial showed. Western European patients in particular appeared to benefit from the intervention. Since vilobelimab displayed an acceptable safety profile in this population, the developers aim to discuss the results with the regulatory authorities. Complement activation (C5a) has been shown to play an important role in severe COVID-19 and vilobelimab is a first-in-class anti-C5a monoclonal antibody that leaves the membrane attach complex (MAC) intact [1]. Since it has been shown that C5a levels are high in patients with severe COVID-19 and related to disease severity [2], Prof. Alexander Vlaar (Amsterdam UMC, the Netherlands) and co-investigators deemed it reasonable to assess C5a inhibition in patients with severe COVID-19. After the successful results of the PANAMO phase 2 study [3], the PANAMO phase 3 study (

Please login to read the full text of the article.

If you have no account yet, please register now.

Posted on